within Pharmacolibrary.Drugs.ATC.L;

model L01AD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.00085,
    adminDuration  = 600,
    adminMass      = 130 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.086,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023333333333333335,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01AD02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lomustine is an alkylating nitrosourea compound used primarily as a chemotherapeutic agent in the treatment of Hodgkin's lymphoma, brain tumors (especially gliomas), and certain other cancers. It is approved for human use and is typically used where other regimens have failed or for recurrent disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data in adult cancer patients after a single oral dose.</p><h4>References</h4><ol><li><p>Lee, FY, et al., &amp; Bleehen, NM (1985). Clinical pharmacokinetics of oral CCNU (lomustine). <i>Cancer chemotherapy and pharmacology</i> 14(2) 125–131. DOI:<a href=&quot;https://doi.org/10.1007/BF00434350&quot;>10.1007/BF00434350</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3971475/&quot;>https://pubmed.ncbi.nlm.nih.gov/3971475</a></p></li><li><p>Kastrissios, H, et al., &amp; Blaschke, TF (1996). Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. <i>Cancer chemotherapy and pharmacology</i> 38(5) 425–430. DOI:<a href=&quot;https://doi.org/10.1007/s002800050506&quot;>10.1007/s002800050506</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8765435/&quot;>https://pubmed.ncbi.nlm.nih.gov/8765435</a></p></li><li><p>Russo, RG, et al., &amp; Bartosek, I (1984). Pharmacokinetics of nitrosoureas: comparison of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) after oral and intravenous administration to rats. <i>Tumori</i> 70(6) 499–502. DOI:<a href=&quot;https://doi.org/10.1177/030089168407000605&quot;>10.1177/030089168407000605</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6531792/&quot;>https://pubmed.ncbi.nlm.nih.gov/6531792</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01AD02;
